Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2

Hwang-Phill Kim, Young-Kwang Yoon, Jin-Won Kim et al. · 2009

Read Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2 by Hwang-Phill Kim, Young-Kwang Yoon, Jin-Won Kim et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0005933.txt.

Description

Some cancer drugs work better as a pair than alone. Hwang-Phill Kim, Young-Kwang Yoon, Jin-Won Kim and colleagues asked in 2009 why lapatinib pairs well with a class of chemotherapy drugs. Lapatinib blocks two growth receptors, EGFR and HER2. The PLOS ONE paper traces its effect on thymidylate synthase, an enzyme tumors often make in excess.

The drug lowers that enzyme by keeping EGFR and HER2 out of the cell nucleus, the team reports. With less of the enzyme, cancer cells grow weaker and the partner drug hits harder. Naming this chain of events gives doctors a clear reason for the pairing and a lead for picking patients most likely to gain.

Catalog record

CREATORHwang-Phill Kim, Young-Kwang Yoon, Jin-Won Kim et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE36 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0005933

Browse the full library · About the Tower of Babel